Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

DIAGNOS Announces the Opening of a Clinical Retinopathy Screening Office in Algeria

V.ADK

BROSSARD, QUEBEC--(Marketwired - Oct. 16, 2014) - DIAGNOS Inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announces today the opening of a clinical retinopathy screening office in Algeria.

Diabetic retinopathy is the most common diabetic eye disease and a leading cause of blindness around the world. It is a treatable disease that, as with most diseases, has a higher treatment success rate in its earlier stages. However, there are generally no symptoms until the disease has progressed to more severe stages, making early detection methods critical to helping prevent vision loss. Algeria has a population of 39.21 million people and, according to the International Diabetes Federation, has a diabetic population of 1.64 million and an additional population of 820,000 who have the disease but are undiagnosed.

"Hadi Chakor, an Algerian ophthalmologist who has worked with us in Montreal since 2012, has returned to his home country to setup a clinic that will provide screening for diabetic retinopathy. Hadi obtained an MD in Algeria in 1995, an MSc in Biomedical Engineering in 2004 from the University of Montreal, and a PhD in Biomedical Science in 2014 from the University of Montreal. He is a member of The Association for Research in Vision and Ophthalmology, The Vision Health Research Network, The Canadian Medical Imaging Network, and The Association of Ophthalmologists of Algeria. Hadi will now be the Country Manager of Diagnos Algeria. Diagnos' goal in Algeria is to maximize the efficiency of preventative screening in the Algerian healthcare system by using telemedicine to connect physicians with patients. By our estimates, about 44% of people suffering from diabetes in Algeria have never even consulted an ophthalmologist, let alone done a yearly checkup as clinical guidelines suggest. Our clinic has been setup to provide 40,000 people a year access to screening and will not only create a physical presence for the company in Algeria, but also add to our increasing presence in the Middle East and North Africa region," said André Larente, DIAGNOS' President.

About DIAGNOS

Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including natural resources, healthcare, and entertainment.

About DIAGNOS Healthcare

DIAGNOS Healthcare is a business division within DIAGNOS Inc., achieving international recognition as leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing. Through its Healthcare division, DIAGNOS offers turn-key diabetic retinopathy screening services to patients in various locations around the world.

Forward-looking information

This document contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these
statements.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Andre Larente, President and CEO
1-877-678-8882 or (450) 678-8882, ext.: 224
alarente@diagnos.ca



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today